202220212020201920182017201620152014 September 07, 2021 Summary ToggleSpero Therapeutics to Present at Three Upcoming Investor Conferences August 31, 2021 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 05, 2021 Summary ToggleSpero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update July 30, 2021 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 29, 2021 Summary ToggleSpero Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021 July 07, 2021 Summary ToggleSpero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference July 02, 2021 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 30, 2021 Summary ToggleSpero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206 June 15, 2021 Summary ToggleSpero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206 May 28, 2021 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination First page First Previous page Previous … Page 2 Current page 3 Page 4 Page 5 … Next page Next Last page Last
